Study confirms the benefit of Paxlovid as an early-stage treatment to prevent COVID-19 hospitalization

A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless of prior immunity or age.

Related Keywords

California ,United States ,La Kaiser Permanente ,Kaiser Permanente ,Emily Henderson ,Sara Tartof ,Pfizer Inc ,Drug Administration ,Southern California ,Kaiser Permanente Southern California Department ,Hospital ,Coronavirus ,Covid 19 ,Health Care ,Immunity ,Research ,Itonavir ,